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Functional bowel disease: 

a challenging frontier in gastroenterology 

Michael Camilleri * 
ABSTRACT: Conquests and challenges in Gastroenterology 
The last 30 years have seen incredible advances in the science and practice of gastroenterology and 
hepatology. In the 1970s, the fiberoptic endoscopic revolution facilitated the visualization of the 
mucosa of a large segment of the gastrointestinal tract and afforded the opportunity for specialized 
studies using histological and biochemical analyses. The impact of fiberoptic endoscopy on 
surveillance or screening for cancer of the colon will be more apparent in the next millennium. 
Novel pharmacological approaches have had a dramatic impact on gastroenterology. Initially, 
histamine H2 receptor antagonists and subsequently the discovery of the proton pump in the 
parietal cell and its inhibition by a number of agents as well as the discovery of the role of 
Helicobacter pylori in peptic ulceration changed the management of peptic ulcer. Gone are the 
long operation lists in which a variety of operations wer.e performed to reduce acid secretion and 
facilitate gastric emptying; thankfully, the iatrogenic complications of those generally 
unphysiological 	 procedures are also less frequently encountered! The recent explosion of 
information on 	inflammatory cytokines and the potential of blocking the inflammatory cascade 
that results in inflammatory bowel disease brings hope to significant improvement in the treatment 
of patients with Crohn's disease and fistulation e.g. with anti-TNF alpha antibodies. In hepatology, 
the advent of transplantation and novel immunosuppressive regimens have brought life to patients 
who would otherwise have suffered severe complications such as variceal bleeding, hepatic 
encephalopathy 	 or death. Laparoscopic surgery, including cholecystectomy, fundoplication, 
Helier's myotomy and partial colectomy, has revolutionized management of several conditions. 
Though organic diseases of the gastrointestinal tract and liver draw most of our attention because 
of the severity of these conditions, it is important to note that the combined prevalence of peptic 
ulceration, inflammatory bowel disease and hepatic cirrhosis is insignificant when compared with 
that of the functional bowel diseases 1.3. At the turn of the century, one of the greatest challenges, 
in terms of direct and indirect costs to society, is presented by these highly prevalent illnesses which 
affect up to 30% of all people in the community at anyone time. It has been estimated that about 
40% of patients seen by gastroenterologists and 10-15% of patients seen by primary care 
physicians in Western societies have one or other form of functional gastrointestinal disorder. 
Research in the last decade leads many to believe that we are on the threshold of significant 
advances in our understanding and treatment of these conditions. 
The objectives of this short article are: to review the control of gut sensorimotor functions relevant 
to the functional disorders; to define functional bowel diseases, their economic burden and impact; 
to review the 	 pathophysiology of these conditions; and to discuss novel pharmacological 
approaches to control the motor and sensory dysfunctions. 
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Control of the sensory/motor functions 
of the gastrointestinal tract 
Although the neuroanatomical pathways involved in 
gasttointestinal motor and sensory function have been 
known for decades, a brief summary of recent advances 
is presented to facilitate an understanding of the 
derangements in the functional diseases. The motor 
function of the gut is controlled by the extrinsic 
sympathetic and parasympathetic fibers, and by the 
intrinsic nervous system. The latter is a vast enteric 
brain with approximately the same number of neurons as 
are found in the mammalian spinal cord. The 
sympathetic nervous system is motor to sphincters and 
relaxatory to nonsphincteric muscle. In contrast, the 
parasympathetic nervous system IS motor to 
nonsphincteric muscle. In the enteric nervous system, 
there are stereotyped hard-wired circuits that serve to 
facilitate certain responses, such as the interdigestive 
migrating motor complex during fasting and the 
response of the gut to feeding. The "law of the intestine" 
is the peristaltic reflex and, in recent years, the 
neurotransmitters and mediators primarily involved in 
this reflex have been the object of intense study. The 
excitatory components of the reflex that result in gut 
contraction are acetylcholine and tachykinins (substance 
P and K); descending inhibition in the aborad region is 
mediated predominantly by VIP and nitric oxide. The 
sensory arm of the peristaltic reflex involves a number of 
transmitters including calcitonin gene related peptide 
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Fig 1 - Functional gastrointestinal disorders: biopsychosocial disorders of high prevalence and impact. 
(CGRP) and serotonin (5HT). Some of the major 
advances in phannacotherapy are based on modulation 
of these transmitters. Sensation of the gut is mediated 
through a 3-order neuron chain, but the initial transducer 
of sensation at the level of the gastrointestinal tract is the 
enteroendocrine cell, which is both a mechanical and a 
chemical transducer4-6 . Visceral signals result in 
reflexes that modulate motor and secretory functions and 
may not al ways project to the conscious brain because 
they synapse with efferent pathways in the prevertebral 
ganglia and in the spinal cord. Perception ultimately 
requires stimulation of the three neurons in the chain to
- bring the sensation up to conscious level. Pain is 
projected through spinal afferents that course along but 
are not sympathetic fibers, entering the cord in the dorsal 
horn. The dorsal horn neuron is a center for modulation 
of sensation. There is a balance between ascending 
infonnation and descending modulation from the 
brainstem that determines the level of central projection 
of incoming signals from the dorsal horn neuron 6. The 
dorsal horn is also a center for modulation of sensation 
since somatic afferents project to its neurons and result 
in viscerosomatic referral as well as modulation of 
sensation. The cerebral hemispheres detennine the level 
of sensation and autonomic responsiveness following gut 
stimuli. There are centers of vigilance in the prefrontal 
cortex, and the limbic system and brainstem reflexes 
change the levels of satiety and modulate autonomic 
responses in pulse and blood pressure to gut stimulation. 
Functional bowel disorders: 
definition and impact 
A functional gastrointestinal disorder consists of 
symptoms that are attributable to the mid or lower 
gastrointestinal tract and that are not attributable to 
anatomical or biochemical disorders l -3. The symptoms 
include abdominal pain, early satiety, nausea, bloating, 
distention, and various symptoms of disordered 
defecation. The three commonest functional bowel 
disorders are irritable bowel syndrome, constipation and 
functional dyspepsia. 
Irritable bowel syndrome is the most common 
functional bowel disorder and it is characterized by 
chronic or recurrent symptoms of lower abdominal pain 
related to bowel movements, change in bowel habit 
(diarrhoea, constipation, or alternating), a sense of 
incomplete rectal evacuation, passage of mucus with 
stool, and abdominal bloating and distention2.3.7. Its 
prevalence in most countries is approximately 10%. 
Constipation is defined in many ways and perceived 
very differently among patients8 ! It is clear that a 
frequency definition of constipation is insufficient, 
although a bowel movement frequency of less than 1 
every 3 days is generally regarded as being outside the 
nonnal range. However, most patients perceive that they 
are constipated when they have to strain excessively or 
have a difficulty passing stool from the rectum or 
completing the evacuation of stool. With such a variety 
of definitions, the prevalence of constipation in the 
community is difficult to ascertain with estimates 
ranging from 3 to 20%9. There is increasing evidence 
that a considerable proportion (perhaps as high as 50% 
in tertiary centers) of patients with constipation has a 
disorder of the process of rectal evacuation 10. Normal 
defecation5 requires coordination of colonic 
contractions, volitional rise in intraabdominal pressure, 
and relaxation of the pelvic floor and anal sphincters 
(Fig. 1). 
Functional dyspepsia is also a common problem 
(prevalence estimated at 20%), and it is characterized by 
chronic or recurrent symptoms of upper abdominal pain 
or "discomfort" which is a summary tenn for such 
symptoms as early satiety, nausea, bloating, and 
vomiting2,l1. In both irritable bowel syndrome and 
functional dyspepsia, no structural or biochemical 
abnormalities are identified. Around 30% of patients 
with irritable bowel syndrome have symptoms consistent 
with functional dyspepsia, either concurrently or at other 
times 12,13. 
There is also overlap in the clinical symptomatology of 
patients with constipation-predominant irritable bowel 
syndrome and those who have constipation that results 
from an evacuation disorder. In patients with suspected 
irritable bowel syndrome, careful evaluation of the 
evacuation process and the dynamics of defecation is 
essential in order to exclude a disorder of rectal 
evacuation, to provide the best treatment and to avoid 
greater direct and indirect costs resulting from 
mismanagement. 
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One of the most important societal perspectives 
resulting from functional bowel disorders is the degree 
of absenteeism that is recorded among patients with 
these conditions 13. For example, it has been estimated 
that patients with irritable bowel syndrome record work 
or school absences of up to 13 days per year compared to 
a normal control population of 5 days per year13. This 
level of absenteeism is equivalent to that of the common 
cold and flu and presents a significant burden to the 
nation's economy. Indeed, it is estimated that 0.1%14 to 
0.5%15 of health care expenditures in industrialized 
countries are attributable to irritable bowel syndrome, 
and that 66-75% of all the economic burden from 
functional gastrointestinal disorders results from indirect 
costs secondary to loss of days at work or school 15. 
Functional bowel disorders constitute a significant 
economic burden in the form of direct costs. It has been 
estimated that annual charges for healthcare delivery for 
irritable bowel syndrome is around 8 billion dollars in 
the U.SI6. More recently the annual costs in 8 major 
industrialized countries in the world were estimated at 
about 41 billion dollars, including 25 billion dollars in 
the U.S. and over 4 billion dollars each in Japan and 
Germany 15 . 
Irritable bowel syndrome 
Irritable bowel syndrome is a biopsychosocial disorder 
in which psychosocial, motility, and sensation 
disturbances (Fig. 1) result in abdominal pain and 
disorders oLdefecation, that is constipation, diarrhea, or 
alternating bowel habits 17 ·18. In community studies, the 
prevalence is around 10% and incidence 1-2% per year. 
The economic burden and impact in terms of healthcare 
utilization have been discussed above. A fourth possible 
etiologic factor that has recently received much attention 
is infection I9.20. Thus, 25-33% of patients with diarrhea­
predominant irritable bowel syndrome give a positive 
history of a previous "enteritis" episode I9.21 . However, 
the persistence of symptoms seems to be more closely 
related to the occurrence of stressful life events and 
hypochondriasis than to changes in physiologic function 
such as transit, sensation, or rectal compliance20. Hence, 
it appears that, in the post-enteritis irritable bowel 
syndrome model, the "mind factor" supercedes the 
influence of the abnormal physiology (e.g., transit, 
sensory thresholds) resulting from the infectious episode. 
Motor dysfunctions are clearly demonstrable in 
patients with irritable bowel syndrome and may 
contribute to some of the symptoms22 . The prominent 
colonic response to feeding results in the familiar 
symptoms of urgency, abdominal pain, and need to have 
a bowel movement in the early postprandial period. 
Abnormal transit profiles such as accelerated small 
bowel and colonic transit in diarrhea-predominant 
irritable bowel syndrome23 constitute one of the major 
rationales for the use of medications that help restore 
normal transit profiles. Patients with urgency and 
diarrhea develop high amplitude , rapidly propagated 
colonic contractions (HAPCs), especially 
postprandiaUy24. 
With greater appreciation of the role of the pelvic floor 
and anal sphincter muscles in the process of evacuation 
(Fig. 2) and of disturbances of the dynamics of 
defecation10, it is clear that pelvic floor disorders may 
produce a syndrome virtually identical to the so-called 
constipation-predominant irritable bowel syndrome. 
Thus, a history of excessive straining, sense of 
incomplete evacuation, or need to digitate the rectum or 
vagina to facilitate emptying of the rectum are all 
features associated with pelvic floor or anal sphincter 
dysfunction8.10.25. In patients with constipation, it is 
essential to perform a careful rectal examination 
including assessments of the anal sphincter tone at rest, 
the ability of the puborectalis to relax during straining lO, 
and the descent of the perineum during straining25 . 
Simple screening tests are available to confirm the 
diagnosis. This differentiation between evacuation 
Fig 2 - Pelvic floor and anal sphincter functions involved in continence and defecation. 
Adapted/rom ref. #8 - Camil/eri M, Thompson WG, Fleshman JW, Pemberton JH. Clinical management of 
intractable constipation. Ann Intern Med 1994;121 :520-8. 
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Fig 3 - Classes of novel medications undergoing trial in functional gastrointestinal disorders. 
Reproduced/ram Camilleri M. Choi M-G: Irritable bowel syndrome. Aliment Pharmacal Ther 1997;11:3 -15. 
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disorder and IBS-constipation has important practical 
implications. For example, a prokinetic agent for 
constipation is unlikely to work in patients with 
evacuation disorders. Much direct and indirect cost 
attributable to irritable bowel syndrome might be saved 
if more attention is placed on the rectal examination 
during appraisal of these patients. 
Another component of motor dysfunction that may 
contribute to heightened sensitivity of the colon is 
spasm. While this is well appreciated by radiologists 
during colon x-ray and by clinicians in practice (the 
colon "squelch" sign on deep palpation of the descending 
or sigmoid segment), it has been difficult to objectively 
demonstrate motor disturbances in the descending or 
sigmoid colon in patients with irritable bowel syndrome. 
Hence, phamlacological approaches to correct motor 
dysfunction have been empirically based [e.g., use of 
antimuscarinic or, more recently, antiserotonergic 
agents I7•18]. 
Colonic and rectal hypersensitivity are very relevant in 
IBS patients with diarrhea and urgency26-28. Indeed, this 
has been proposed as a biological marker of the 
condition28 , although the lack of responsiveness of rectal 
hypersensitivity in clinical trials29 arid its poor 
correlation with symptom responses question whether it 
can be used as a biological marker30 . Anxiety, 
psychosensory function and limbic system activation 
may contribute to the increased rectocolonic 
sensitivity31-33. In summary, the evidence for 
hypersensitivity in irritable bowel syndrome is 
considerable, but the proof of its clinical relevance will 
depend on the development of effective therapies and 
documentation of clinical benefit by restoring normal 
sensation34 . 
Several novel approaches to treatment of irritable 
Sympathetic "" somatostatin analogs 
11 S2,3,4 
altered 
sensation 
bowel syndrome are based on these improved insights on 
the motor and sensory functions of the colon and rectum 
(Fig. 3). Thus, novel 5-HT4 agonists which stimulate 
colonic transit and motor function [prucalopride35 , 
tegaserod36] are being developed for the constipation and 
pain predominant irritable bowel syndrome. The 
consistent relief of pain without side effects in irritable 
bowel syndrome has always presented a considerable 
challenge. In the past, anticholinergic agents have been 
used37, but they tend to induce tachyphylaxis and 
systemic side effects. The appreciation of the role of 5­
HT3 receptors in visceral afferents, as well as the 
demonstration that a 5-HT3 antagonist can reduce the 
colonic motor response to meal ingestion38 have led to 
the large phase IT and phase III clinical trials with a 
novel 5-HT3 antagonist, alosetron. Recent studies from 
phase Il39 and phase m40 trials suggest that this 
medication provides adequate relief of pain and 
discomfort, while reducing frequency and urgency and 
improving consistency of stool in diarrhea-predominant 
IBS patients (Fig. 4). 
Another pharmacological approach that has been 
proposed is to use kappa opioid (peripheral) agonists in 
order to reduce the pain sensation arising in the gut 
without having any central effects41 . In the next 5 to IQ 
years we should see further validation of these concepts 
for the purpose of treating irritable bowel syndrome. At 
the experimental level, it is also known that alpha-2 
adrenergic agents modulate motor and sensory functions 
of the bowel (Fig. 5), particularly the sensation of pain 
arising during mechanical distention of the colon42 . 
Thus, studies at Mayo Clinic showed that the alpha-2 
agonist, . clonidine, reduces pain sensation but has no 
effect on gas sensation during distention experiments. 
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Fig 4 - Comparison of effects of a novel 5HT3 antagonist, 
alosetron, and placebo on abdominal pain (upper panel, 
1 mg b.i.d. alosetron vs . placebo) and frequency of 
defecation (4 doses of alosetron vs. placebo) in female 
patients with diarrhea-predominant 18S. Note that a 
significantly larger percentage of patients report 
adequate relief of pain compared to placebo. 
Adapted from re/. #39 - Camilleri M, Mayer EA . Drossman 
DA. Heath A. Dukes GE. McSorley D, Kong S. Mangel AW, 
Northcutt AR. Improvement in pain and bowel function in 
female irritable bowel patients with alosetron . a 5HT3­
receptor antagonist. Alimellt Pharmacal Ther (ill press) 
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Constipation 
Constipation is a very common clinical problem, and a 
questionnaire study in Olmsted County, Minnesota 
demonstrated that up to 20% of patients report 
constipation9 . Approximately 40% of such patients have 
historical evidence of needing to strain excessively to 
pass bowel movements. These features might suggest 
that they also have a component of an evacuation 
disorder, although the questionnaire-based data do not 
allow a sufficient distinction between an evacuation 
problem and slow transit constipation. "In a tertiary 
center study , 50% of 70 patients with ~evere, 
unresponsive constipation referred to a single 
gastroenterologist over a 3-year period had impaired 
evacuation, and the remainder of patients had either 
nom1al or slow transit constipation 10. 
Physiological characterization of constipated patients 
is important for several reasons. First, it has been shown 
that, among patients with slow transit constipation, drug­
induced constipation, or evacuation disorders, 
supplementation of up to 30 grams of fiber per day did 
not result in any improvement in constipation43 . Second, 
Fig 5 - Effects of adrenergic agents on human colonic 
sensation during mechanical distentions (4-32mmHg). 
Note clonidine markedly reduces pain but not gas 
sensation, suggesting a specific anti nociceptive action. 
Reproduced from re/. #42- Bharucha AE. Camilleri M. 
Zinsmeister AR. Hanson RB. Adrellergic modulatioll of human 
colonic motor and sensory function. Am J Physiol 
1997;273 :G997-1006. 
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it is important to identify evacuation disorders because a 
biofeedback treatment program with muscle relaxation 
of anal sphincters and puborectalis results in a 70% or 
greater cure rate for the constipation 44. Surgical and 
other aggressive strategies that have been used in the 
past for evacuation disorders have been shown to be 
either unnecessary or damaging to patients , resulting in 
incontinence. Finally, characterization of pelvic floor 
function and transit profiles by radiopaque markers or 
scintigraphy45.46 facilitates a more physiological 
approach to relieving constipation. Thus, patients with 
slow transit constipation tend to benefit from fiber, 
osmotic laxatives, and stimulant laxatives (e.g. , 
bisacodyl), whereas patients with evacuation disorders 
do not need medication other than fiber supplementation 
after the pelvic floor is rehabilitated. 
Functional dyspepsia 
Functional dyspepsia is also a biopsychosocial 
disorder in which disturbances of psychosocial function , 
altered motility, and altered sensation (Fig. 1) interact to 
induce the condition47 . Whereas, much time and effort 
has been spent in the last decade exploring the role of 
infectious organisms such as Helicobacter pylori in the 
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Fig 6 - Measurement of gastric accommodation response with an intragastric balloon is inflated at 
intragastric barostatically-controlled balloon. Note the greater increase in different pressures, cisapride results in 
volume (suggesting greater gastric accommodation) in the healthy control increased accommodation of the 
compared to two patients with functional (nonulcer) dyspepsia. stomach, but it also lowers (rather than 
Reproduced from rej. #57 . Thumshirn M, Camilleri M, Saslow SB, WilIiams DE, raises) the threshold pressures for the 
Burton DD. Ham'on RB. Gastric accommodation in nonulcer dyspepsia and the roles induction of discomfort61 . Similarly, 
ofHelicobacter pylori infection and vagal function. Gut 1999;44:55·64. work at Mayo Clinic in healthy subjects 
has demonstrated that the nitric oxide 
donor, nitroglycerin, results in marked, 
dose-related relaxation of the stomach 
600 but no change in pain sensation inMEAL .. ~IControl • r'VVvvV 5 minutes _ DJ 	 response to balloon distention62. In 
fact, there was a worsening in the3 I\) 
-------------. 0":: (3 sensation of bloating in these subjects. 
---- -------- ---- -- ---- -- [  ~ By way of contrast, clonidine, an alpha­
2 adrenergic agonist with central 
antinociceptive action, was associated 
with reduction in pain sensation during 
1 c: gastric distention; relaxation in gastric600 3 wall tension due to the clonidineNUDHp+ .. .~L~_ (J) accounted for about 40% of the 
variance in pain sensation62. These 
-------------------- 0 data suggest that novel approaches to 
therapy for functional dyspepsia will 
require a visceral antinociceptive effect 
rather than an exclusive relaxatory action.context of nonulcer dyspepsia48.49, it is now clear from 
eradication and outcome studies that the organism is 
Conclusionprobably an innocent bystander in the absence of 
ulceration. Depending upon how it is defined in 
Insights into the pathophysiology of motor and sensorydifferent epidemiologic studies, the prevalence of 
functions of the functional gastrointestinal disorders, asfunctional dyspepsia ranges from 5% to 25%12. As with 
well as collaboration between academia and industry tothe irritable bowel syndrome, this disorder results in 
understand the conditions and develop novel therapiesconsiderable disturbance of quality of life, social 
augur well for major advances in the functionalfunction, and healthcare utilization 15. 
gastrointestinal disorders. While the last quarter of theAmong the mechanisms of nonulcer dyspepsia in 
20th century was characterized by tremendous advancesadults, approximately 30% have impaired gastric 
in endoscopy, surgical approaches including laparoscopyemptying of solids50·53 , and these patients respond to 
and transplantation, and novel pharmacology for acidprokinetic medications53 . A second major motor 
hypersecretion and inflammation, we appear to be on theabnormality is impaired postprandial gastric 
threshold of very significant therapeutic advances in theaccommodation (Fig. 6), which is associated with early 
context of the highly prevalent functional bowelsatiety and weight loss 54. 
disorders. The spiraling costs of healthcare andThe other major pathophysiologic disturbance of 
economic burden from indirect cost for these conditionsfunctional dyspepsia is gastric hypersensitivity55.57 . The 
require a concerted effort to respond to the challengeselastic properties (compliance) of the stomach are 
presented to our patients and to society.unimpaired55.57 , yet patients experience pain or 
discomfort at lower thresholds. Thus, the visceral 
Acknowledgementsafferents are considered hypersensitive. Dyspeptic 
patients also have evidence of hyperalgesia, since the 
I wish to thank my colleagues and former fellows (Drs.same stimulus produces higher pain scores than in 
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Michael D. O'Brien, Manfred von der Ohe, Charlene M.gastric accommodation has been noted in association 
Prather, Miriam Thumshim, and Mario Vassallo) whosewith hypersensitivity in the fasting or postprandial 
individual contributions have been acknowledged in thisperiods 54.57. This lack of accommodation may suggest 
manuscript and Mrs. Cindy Stanislav for excellentthat a pharmacological relaxation of the stomach would 
secretarial support.improve the dyspeptic symptoms of such patients. 

Relatively simple tests58.60 can assess the degree of 
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